Back to top
more

Alcon (ALC)

(Delayed Data from NYSE)

$80.92 USD

80.92
1,527,434

-1.09 (-1.33%)

Updated May 13, 2024 04:00 PM ET

After-Market: $80.91 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Increased digital health adoption and growing pharmacy sales are likely to have contributed to CVS Health's (CVS) Q1 performance.

The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical

by Zacks Equity Research

Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.

Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.

Urmimala Biswas headshot

3 Medical Product Stocks Poised to Beat This Earnings Season

by Urmimala Biswas

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

LabCorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust demand for iTero scanners and increasing Invisalign case submissions are expected to have contributed to Align Technology's (ALGN) Q1 performance.

Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed

by Zacks Equity Research

Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.

Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.

Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth

by Zacks Equity Research

In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.

Alcon (ALC) Publishes Dividend, New Board Member Addition Plans

by Zacks Equity Research

Alcon's 2022 AGM is set to take place in a closed format without the personal presence of shareholders.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch

by Zacks Equity Research

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

Alcon (ALC) Surgical Arm Expands, International Growth Slows

by Zacks Equity Research

In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.

Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.

Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise

by Zacks Equity Research

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief

by Zacks Equity Research

Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.

Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption

by Zacks Equity Research

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.

Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

by Zacks Equity Research

Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

by Zacks Equity Research

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves

by Zacks Equity Research

Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.

Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases

by Zacks Equity Research

Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.